As you say, the trial is double blinded and neither the company nor the regulator knows its result.
I do find it interesting though about the delayed PR, it certainly seems material information.
But considering there is an active trial to consider, I trust the company had guidance on this and acted appropriately.
The last thing they would want to do would be to jeopardize the trial.
It does seem odd... but come to think about it, it was publicly published, thus the company was not withholding material information.
With this in mind, it makes sense the company took some time to decided whether or how to PR the information already in the public domain.